ARS Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
ARS Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2024.
  • ARS Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$19.1M, a 28.7% decline year-over-year.
  • ARS Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$49.1M, a 20.3% increase year-over-year.
  • ARS Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$54.4M, a 56.8% decline from 2022.
  • ARS Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$34.7M, a 71.3% decline from 2021.
  • ARS Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$20.2M, a 38.6% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$49.1M -$19.1M -$4.26M -28.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$44.8M -$12.5M +$4.85M +27.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$49.7M -$10.3M +$4.67M +31.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$54.4M -$7.17M +$7.26M +50.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$61.6M -$14.9M -$8.28M -126% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$53.3M -$17.4M -$11M -171% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$42.4M -$15M -$7.71M -106% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$34.7M -$14.4M -$60.2M -132% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 $25.5M -$6.58M +$16.1M +70.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $9.45M -$6.42M +$18.1M +73.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$8.63M -$7.25M +$11.6M +61.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$20.2M $45.8M +$58.9M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-23
Q3 2021 -$79.1M -$22.7M -$14.5M -179% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 -$64.6M -$24.5M -$18M -279% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$46.5M -$18.9M -$13.6M -257% Jan 1, 2021 Mar 31, 2021 10-Q 2022-08-11
Q4 2020 -$32.9M -$13.1M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$8.12M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$6.47M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$5.28M Jan 1, 2020 Mar 31, 2020 10-Q 2021-08-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.